MoonLake Immunotherapeutics (NASDAQ: MLTX) jumped about 6.5% in premarket trading after the FDA granted Fast Track designation for the company’s sonelokimab (SLK) program in moderate-to-severe…
February 02, 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX) jumped about 6.5% in premarket trading after the FDA granted Fast Track designation for the company’s sonelokimab (SLK) program in moderate-to-severe…